Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Alzheimer's Disease

  Free Subscription

Articles published in J Neurol

Retrieve available abstracts of 62 articles:
HTML format

Single Articles

    March 2024
  1. PENG M, Yuan S, Lu D, Ling Y, et al
    Dietary inflammatory index, genetic susceptibility and risk of incident dementia: a prospective cohort study from UK biobank.
    J Neurol. 2024;271:1286-1296.
    PubMed     Abstract available

    February 2024
  2. SUBOTIC A, Gee M, Nelles K, Ba F, et al
    Gray matter loss relates to dual task gait in Lewy body disorders and aging.
    J Neurol. 2024;271:962-975.
    PubMed     Abstract available

    January 2024
  3. GENG C, Meng K, Tang Y
    Identifying the mediating role of inflammation on the relationship between socioeconomic status and Alzheimer's disease: a Mendelian randomization analysis and mediation analysis.
    J Neurol. 2024 Jan 22. doi: 10.1007/s00415-023-12176.
    PubMed     Abstract available

  4. HENNEY AE, Gillespie CS, Alam U, Hydes TJ, et al
    High intake of ultra-processed food is associated with dementia in adults: a systematic review and meta-analysis of observational studies.
    J Neurol. 2024;271:198-210.
    PubMed     Abstract available

    December 2023
  5. MASSA F, Martinuzzo C, Gomez de San Jose N, Pelagotti V, et al
    Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease.
    J Neurol. 2023 Dec 29. doi: 10.1007/s00415-023-12154.
    PubMed     Abstract available

  6. RONAT L, Hanganu A, Chylinski D, Van Egroo M, et al
    Prediction of cognitive decline in healthy aging based on neuropsychiatric symptoms and PET-biomarkers of Alzheimer's disease.
    J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12131.
    PubMed     Abstract available

    November 2023
  7. ST-GEORGES MA, Wang L, Chapleau M, Migliaccio R, et al
    Social cognition and behavioral changes in patients with posterior cortical atrophy.
    J Neurol. 2023 Nov 30. doi: 10.1007/s00415-023-12089.
    PubMed     Abstract available

  8. PEREZ-MILLAN A, Borrego-Ecija S, Falgas N, Junca-Parella J, et al
    Cortical thickness modeling and variability in Alzheimer's disease and frontotemporal dementia.
    J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12087.
    PubMed     Abstract available

  9. VRILLON A, Ashton NJ, Karikari TK, Gotze K, et al
    Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study.
    J Neurol. 2023 Nov 11. doi: 10.1007/s00415-023-12066.
    PubMed     Abstract available

    September 2023
  10. STAM D, Rosseel S, De Winter FL, Van den Bossche MJA, et al
    Facial expression recognition deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic investigation of effects of phenotypic variant, task modality, geographical region and symptomatic specificity.
    J Neurol. 2023 Sep 6. doi: 10.1007/s00415-023-11927.
    PubMed     Abstract available

  11. CHAN E, Bonifacio GB, Harrison C, Banerjee G, et al
    Domain-specific neuropsychological investigation of CAA with and without intracerebral haemorrhage.
    J Neurol. 2023 Sep 6. doi: 10.1007/s00415-023-11977.
    PubMed     Abstract available

  12. DAMSGAARD L, Janbek J, Laursen TM, Waldemar G, et al
    Healthcare utilization prior to a diagnosis of young-onset Alzheimer's disease: a nationwide nested case-control study.
    J Neurol. 2023 Sep 5. doi: 10.1007/s00415-023-11974.
    PubMed     Abstract available

    July 2023
  13. PENA-BAUTISTA C, Alvarez-Sanchez L, Ferrer-Cairols I, Garcia-Valles L, et al
    Assessment of COVID-19 lockdown effect on early Alzheimer Disease progression.
    J Neurol. 2023 Jul 28. doi: 10.1007/s00415-023-11899.
    PubMed     Abstract available

  14. MIZUTANI Y, Ohdake R, Tatebe H, Higashi A, et al
    Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease.
    J Neurol. 2023 Jul 22. doi: 10.1007/s00415-023-11875.
    PubMed     Abstract available

  15. SAW AM, Hrastelj J, Robertson NP
    Path from discovery to recovery: therapeutic and diagnostic advances in Alzheimer's dementia.
    J Neurol. 2023 Jul 3. doi: 10.1007/s00415-023-11840.

    June 2023
  16. KUCIKOVA L, Zeng J, Munoz-Neira C, Muniz-Terrera G, et al
    Genetic risk factors of Alzheimer's Disease disrupt resting-state functional connectivity in cognitively intact young individuals.
    J Neurol. 2023 Jun 26. doi: 10.1007/s00415-023-11809.
    PubMed     Abstract available

    April 2023
  17. LING Y, Yuan S, Huang X, Tan S, et al
    The association of night shift work with the risk of all-cause dementia and Alzheimer's disease: a longitudinal study of 245,570 UK Biobank participants.
    J Neurol. 2023 Apr 6. doi: 10.1007/s00415-023-11672.
    PubMed     Abstract available

  18. FERRUCCI R, Cuffaro L, Capozza A, Rosci C, et al
    Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19.
    J Neurol. 2023;270:1823-1834.
    PubMed     Abstract available

  19. TAYLOR NL, Shine JM
    A whole new world: embracing the systems-level to understand the indirect impact of pathology in neurodegenerative disorders.
    J Neurol. 2023;270:1969-1975.
    PubMed     Abstract available

  20. CONSTANTINIDES VC, Tentolouris-Piperas V, Paraskevas GP, Pyrgelis ES, et al
    Hippocampal subfield volumetry in corticobasal syndrome of diverse underlying pathologies.
    J Neurol. 2023;270:2059-2068.
    PubMed     Abstract available

    March 2023
  21. SEMENKOVA A, Piguet O, Johnen A, Schroeter ML, et al
    The Behavioural Dysfunction Questionnaire discriminates behavioural variant frontotemporal dementia from Alzheimer's disease dementia and major depressive disorder.
    J Neurol. 2023 Mar 23. doi: 10.1007/s00415-023-11666.
    PubMed     Abstract available

  22. FILIPPI M, Cecchetti G, Cagnin A, Marra C, et al
    Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer's disease: an expert opinion and practical guideline.
    J Neurol. 2023 Mar 9. doi: 10.1007/s00415-023-11642.
    PubMed     Abstract available

    February 2023
  23. JISKOOT LC, Russell LL, Greaves CV, van Schaik E, et al
    Addition of the FTD Module to the Neuropsychiatric Inventory improves classification of frontotemporal dementia spectrum disorders.
    J Neurol. 2023 Feb 22. doi: 10.1007/s00415-023-11596.
    PubMed     Abstract available

  24. CHU H, Huang C, Miao Y, Ren C, et al
    The association of subjective sleep characteristics and plasma biomarkers of Alzheimer's disease pathology in older cognitively unimpaired adults with higher amyloid-beta burden.
    J Neurol. 2023 Feb 20. doi: 10.1007/s00415-023-11626.
    PubMed     Abstract available

  25. EDWARDS M, Corkill R
    Disease-modifying treatments in Alzheimer's disease.
    J Neurol. 2023 Feb 16. doi: 10.1007/s00415-023-11602.

    January 2023
  26. CRETIN B, Philippi N, Bousiges O, Blanc F, et al
    Transient epileptic amnesia: a retrospective cohort study of 127 cases, including CSF amyloid and tau features.
    J Neurol. 2023 Jan 30. doi: 10.1007/s00415-023-11576.
    PubMed     Abstract available

  27. FU X, Chu C, Pang Y, Cai H, et al
    A blood mRNA panel that differentiates Alzheimer's disease from other dementia types.
    J Neurol. 2023 Jan 7. doi: 10.1007/s00415-023-11558.
    PubMed     Abstract available

    December 2022
  28. LIAMPAS I, Siokas V, Lyketsos CG, Dardiotis E, et al
    Associations between neuropsychiatric symptoms and incident Alzheimer's dementia in men versus women.
    J Neurol. 2022 Dec 26. doi: 10.1007/s00415-022-11541.
    PubMed     Abstract available

  29. FAN Z, Li Z, Zhao S, Chen Y, et al
    Salivary Abeta(1-42) may be a quick-tested biomarker for clinical use in Alzheimer's disease: a meta-analysis.
    J Neurol. 2022 Dec 23. doi: 10.1007/s00415-022-11509.
    PubMed     Abstract available

  30. LEOCADI M, Canu E, Paldino A, Agosta F, et al
    Awareness impairment in Alzheimer's disease and frontotemporal dementia: a systematic MRI review.
    J Neurol. 2022 Dec 13. doi: 10.1007/s00415-022-11518.
    PubMed     Abstract available

    November 2022
  31. LI Y, Chen Z, Wang Q, Lv X, et al
    Identification of hub proteins in cerebrospinal fluid as potential biomarkers of Alzheimer's disease by integrated bioinformatics.
    J Neurol. 2022 Nov 18. pii: 10.1007/s00415-022-11476.
    PubMed     Abstract available

  32. LOPEZ-ORTIZ S, Lista S, Valenzuela PL, Pinto-Fraga J, et al
    Effects of physical activity and exercise interventions on Alzheimer's disease: an umbrella review of existing meta-analyses.
    J Neurol. 2022 Nov 7. pii: 10.1007/s00415-022-11454.
    PubMed     Abstract available

    October 2022
  33. FERNANDES M, Mari L, Chiaravalloti A, Paoli B, et al
    (18)F-FDG PET, cognitive functioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment.
    J Neurol. 2022;269:5356-5367.
    PubMed     Abstract available

    September 2022
  34. ACHENBACH J, Faissner S, Saft C
    Resurrection of sildenafil: potential for Huntington's Disease, too?
    J Neurol. 2022;269:5144-5150.
    PubMed     Abstract available

  35. RHODUS EK, Barber J, Kryscio RJ, Abner EL, et al
    Frontotemporal neurofibrillary tangles and cerebrovascular lesions are associated with autism spectrum behaviors in late-life dementia.
    J Neurol. 2022;269:5105-5113.
    PubMed     Abstract available

  36. ALTUNA M, Larumbe R, Zelaya MV, Moreno S, et al
    Progressive cognitive impairment and familial spastic paraparesis due to PRESENILIN 1 mutation: anatomoclinical characterization.
    J Neurol. 2022;269:4853-4862.
    PubMed     Abstract available

    August 2022
  37. SINGH NA, Graff-Radford J, Machulda MM, Schwarz CG, et al
    Atypical Alzheimer's disease phenotypes with normal or borderline PET biomarker profiles.
    J Neurol. 2022 Aug 24. pii: 10.1007/s00415-022-11330.
    PubMed     Abstract available

  38. DOUNAVI ME, Newton C, Jenkins N, Mak E, et al
    Macrostructural brain alterations at midlife are connected to cardiovascular and not inherited risk of future dementia: the PREVENT-Dementia study.
    J Neurol. 2022;269:4299-4309.
    PubMed     Abstract available

    July 2022
  39. MENARDI A, Dotti L, Ambrosini E, Vallesi A, et al
    Transcranial magnetic stimulation treatment in Alzheimer's disease: a meta-analysis of its efficacy as a function of protocol characteristics and degree of personalization.
    J Neurol. 2022 Jul 4. pii: 10.1007/s00415-022-11236.
    PubMed     Abstract available

  40. LAFORCE RJ, Dallaire-Theroux C, Racine AM, Dent G, et al
    Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1.
    J Neurol. 2022;269:3579-3587.
    PubMed     Abstract available

  41. ROSENBLUM Y, Shiner T, Bregman N, Fahoum F, et al
    Event-related oscillations differentiate between cognitive, motor and visual impairments.
    J Neurol. 2022;269:3529-3540.
    PubMed     Abstract available

    June 2022
  42. CLARK E, Faruque S, Mutebi C, Nagirimadugu NV, et al
    Investigating the relationship between mild traumatic brain injury and Alzheimer's disease and related dementias: a systematic review.
    J Neurol. 2022 Jun 1. pii: 10.1007/s00415-022-11186.
    PubMed     Abstract available

    March 2022
  43. ISELLA V, Crivellaro C, Formenti A, Musarra M, et al
    Validity of cingulate-precuneus-temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer's Disease.
    J Neurol. 2022 Mar 26. pii: 10.1007/s00415-022-11086.
    PubMed     Abstract available

  44. GIACOMUCCI G, Mazzeo S, Bagnoli S, Ingannato A, et al
    Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.
    J Neurol. 2022 Mar 14. pii: 10.1007/s00415-022-11055.
    PubMed     Abstract available

  45. BANERJEE G, Forsgard N, Ambler G, Keshavan A, et al
    Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis.
    J Neurol. 2022;269:1470-1475.
    PubMed     Abstract available

    February 2022
  46. CORRIVEAU-LECAVALIER N, Machulda MM, Botha H, Graff-Radford J, et al
    Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases.
    J Neurol. 2022 Feb 25. pii: 10.1007/s00415-022-11025.
    PubMed     Abstract available

    January 2022
  47. LARDEUX P, Fourier A, Peter E, Dorey A, et al
    Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis.
    J Neurol. 2022;269:377-388.
    PubMed     Abstract available

    December 2021
  48. SCHUMACHER J, Taylor JP, Hamilton CA, Firbank M, et al
    Functional connectivity in mild cognitive impairment with Lewy bodies.
    J Neurol. 2021;268:4707-4720.
    PubMed     Abstract available

  49. SANTORO JD, Pagarkar D, Chu DT, Rosso M, et al
    Neurologic complications of Down syndrome: a systematic review.
    J Neurol. 2021;268:4495-4509.
    PubMed     Abstract available

    November 2021
  50. ROSSO M, Chu D
    Gaetano Perusini (1879-1915).
    J Neurol. 2021;268:4400-4401.

    October 2021
  51. CONTADOR J, Perez-Millan A, Guillen N, Tort-Merino A, et al
    Baseline MRI atrophy predicts 2-year cognitive outcomes in early-onset Alzheimer's disease.
    J Neurol. 2021 Oct 19. pii: 10.1007/s00415-021-10851.
    PubMed     Abstract available

  52. PLEEN J, Townley R
    Alzheimer's disease clinical trial update 2019-2021.
    J Neurol. 2021 Oct 5. pii: 10.1007/s00415-021-10790.
    PubMed     Abstract available

  53. ARMON C, Wolfson S, Margalit R, Avraham L, et al
    Estimating the X chromosome-mediated risk for developing Alzheimer's disease.
    J Neurol. 2021 Oct 5. pii: 10.1007/s00415-021-10826.
    PubMed     Abstract available

  54. OLIVIERI P, Lebouvier T, Hardouin JB, Courtemanche H, et al
    LeSCoD: a new clinical scale for the detection of Lewy body disease in neurocognitive disorders.
    J Neurol. 2021;268:3886-3896.
    PubMed     Abstract available

    July 2021
  55. ULUGUT H, Stek S, Wagemans LEE, Jutten RJ, et al
    The natural history of primary progressive aphasia: beyond aphasia.
    J Neurol. 2021 Jul 3. pii: 10.1007/s00415-021-10689.
    PubMed     Abstract available

    June 2021
  56. MOHAMED AZ, Nestor PJ, Cumming P, Nasrallah FA, et al
    Traumatic brain injury fast-forwards Alzheimer's pathology: evidence from amyloid positron emission tomorgraphy imaging.
    J Neurol. 2021 Jun 30. pii: 10.1007/s00415-021-10669.
    PubMed     Abstract available

    May 2021
  57. LIU X, Dounavi ME, Ritchie K, Wells K, et al
    Higher midlife CAIDE score is associated with increased brain atrophy in a cohort of cognitively healthy middle-aged individuals.
    J Neurol. 2021;268:1962-1971.
    PubMed     Abstract available

    April 2021
  58. WEI Y, Liu M, Wang D
    The propagation mechanisms of extracellular tau in Alzheimer's disease.
    J Neurol. 2021 Apr 28. pii: 10.1007/s00415-021-10573.
    PubMed     Abstract available

  59. FIRBANK MJ, O'Brien JT, Durcan R, Allan LM, et al
    Mild cognitive impairment with Lewy bodies: blood perfusion with arterial spin labelling.
    J Neurol. 2021;268:1284-1294.
    PubMed     Abstract available

    January 2021
  60. ORAD RI, Shiner T
    Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia: an update on imaging modalities.
    J Neurol. 2021 Jan 29. pii: 10.1007/s00415-021-10402.
    PubMed     Abstract available

  61. SEGHEZZO G, Van Hoecke Y, James L, Davoren D, et al
    Feasibility study of assessing the Preclinical Alzheimer Cognitive Composite (PACC) score via videoconferencing.
    J Neurol. 2021 Jan 26. pii: 10.1007/s00415-021-10403.
    PubMed     Abstract available

    May 2020
  62. DONAGHY PC, Firbank M, Mitra D, Petrides G, et al
    Microbleeds in dementia with Lewy bodies.
    J Neurol. 2020;267:1491-1498.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.